Alnylam Pharmaceuticals, Inc. revenue by year
Over the 10 fiscal years shown, revenue went from $47.16M (year ended Dec 31, 2016) to $3.71B (year ended Dec 31, 2025), a compound annual growth rate of 62.4%. The fastest growth was +193.4% in the year ended Dec 31, 2019; the weakest year was −16.7% (year ended Dec 31, 2018).
Annual revenue
| Fiscal year ended | Revenue (USD) | Change | XBRL concept | Reported in |
|---|---|---|---|---|
| Dec 31, 2025 | $3.71B | +65.2% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 12, 2026 |
| Dec 31, 2024 | $2.25B | +23.0% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 12, 2026 |
| Dec 31, 2023 | $1.83B | +76.2% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 12, 2026 |
| Dec 31, 2022 | $1.04B | +22.9% | Revenues | 10-K filed Feb 23, 2023 |
| Dec 31, 2021 | $844.29M | +71.3% | Revenues | 10-K filed Feb 23, 2023 |
| Dec 31, 2020 | $492.85M | +124.3% | Revenues | 10-K filed Feb 23, 2023 |
| Dec 31, 2019 | $219.75M | +193.4% | Revenues | 10-K filed Feb 10, 2022 |
| Dec 31, 2018 | $74.91M | −16.7% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 11, 2021 |
| Dec 31, 2017 | $89.91M | +90.7% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 13, 2020 |
| Dec 31, 2016 | $47.16M | — | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 14, 2019 |
Alnylam Pharmaceuticals, Inc. reported revenue under 2 different XBRL concepts across these years (often after the 2018 change in revenue-recognition rules, ASC 606). Each row shows the concept used, so you can judge comparability.
Quarterly revenue
Quarters reported in 10-Q filings. Fourth quarters are usually reported only inside the annual 10-K, so they are not listed separately here; we do not estimate them.
| Quarter | Revenue (USD) | vs same quarter a year earlier | Source |
|---|---|---|---|
| 3 months ended Sep 30, 2026 | $1.46B | +16.7% | 10-Q filed Oct 29, 2026 |
| 3 months ended Jun 30, 2026 | $1.29B | +66.9% | 10-Q filed Jul 30, 2026 |
| 3 months ended Sep 30, 2025 | $1.25B | +149.3% | 10-Q filed Oct 29, 2026 |
| 3 months ended Jun 30, 2025 | $773.69M | +17.3% | 10-Q filed Jul 30, 2026 |
| 3 months ended Mar 31, 2025 | $594.19M | +20.2% | 10-Q filed May 1, 2025 |
| 3 months ended Sep 30, 2024 | $500.92M | −33.3% | 10-Q filed Oct 30, 2025 |
| 3 months ended Jun 30, 2024 | $659.83M | +107.0% | 10-Q filed Jul 31, 2025 |
| 3 months ended Mar 31, 2024 | $494.33M | +54.8% | 10-Q filed May 1, 2025 |
Source: SEC EDGAR XBRL company facts for CIK 1178670 (raw data). Most recent filing in this dataset: 10-Q filed Oct 29, 2026. SEC data file dated Nov 3, 2026; page built Nov 5, 2026. Figures are as most recently reported, including restatements. How we select figures.